Perspectives - Page 2

Real World Evidence Expertise in Duchenne’s and Beckers Muscular Dystrophy

The PHARMO Institute, part of Lumanity, delivers research insights into Duchenne's muscular dystrophy (DMD) and Beckers muscular dystrophy (BeMD), and the PHARMO Data Network offers great research potential for these rare disease populations.

Resource

Biopharma Commercialization Readiness: What Leaders Need to Consider

Resource

Upgrading ADCs to the Next Level: What Does the Future of Antibody Drug Conjugates Look Like?

On-Demand Webinar Nov 20, 2024

Searching in a More Complete Haystack: Using Real World Data to Guide Precision Oncology Drug Development

On-Demand Webinar Nov 13, 2024

The IRA Impact on Innovation in Drug Development

On-Demand Webinar Nov 13, 2024

How to: Conduct an HTA Landscaping Review

Lumanity’s Linda Murphy provides insights into how to conduct an HTA landscaping review, tailoring it your company's needs, why it's useful, and key considerations.

Resource

Payer Value Communications: Advancing Effective Value Messages in an Evolving Access Landscape

On-Demand Webinar Nov 8, 2024

Case Study Scenario: IRA Threatens Advancement in Fight Against Rare Cancers

View Nov 7, 2024

Healthcare’s Bold New Reality: Key Insights from HLTH 2024

View Nov 5, 2024

Regional Considerations and Challenges in Integrated Evidence Generation Planning (IEGP)

Podcast Nov 5, 2024

Drill Down & Catch Up: The Role of Biomarkers in Neurodegenerative Disease

Lumanity offers extensive experience-based strategic guidance and insights in the field of neuroscience. Our goal is to provide our clients with actionable solutions that de-risk and optimize the development and commercialization of therapies, ultimately improving the lives of patients who are impacted across a range of conditions.

View Nov 4, 2024